Published in J Immunol on September 01, 2007
Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther (2010) 9.13
The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov (2010) 2.23
Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo. Nat Biotechnol (2009) 1.90
Translating costimulation blockade to the clinic: lessons learned from three pathways. Immunol Rev (2009) 1.66
Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T-cells. Br J Pharmacol (2010) 1.65
Interleukin (IL)-1 promotes allogeneic T cell intimal infiltration and IL-17 production in a model of human artery rejection. J Exp Med (2008) 1.41
Challenges and approaches for the development of safer immunomodulatory biologics. Nat Rev Drug Discov (2013) 1.35
Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-beta receptor. J Immunother (2008) 1.25
Surrogate end points in the design of immunotherapy trials: emerging lessons from type 1 diabetes. Nat Rev Immunol (2010) 1.22
Inflammatory findings on species extrapolations: humans are definitely no 70-kg mice. Arch Toxicol (2013) 1.14
Why animal studies are often poor predictors of human reactions to exposure. J R Soc Med (2009) 1.13
Use of pharmacokinetic/ pharmacodynamic modelling for starting dose selection in first-in-human trials of high-risk biologics. Br J Clin Pharmacol (2008) 1.10
A novel form of 4-1BBL has better immunomodulatory activity than an agonistic anti-4-1BB Ab without Ab-associated severe toxicity. Vaccine (2009) 1.09
Signaling signatures and functional properties of anti-human CD28 superagonistic antibodies. PLoS One (2008) 1.09
Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies. MAbs (2010) 1.06
Cytokines as biomarkers of nanoparticle immunotoxicity. Chem Soc Rev (2013) 1.05
The calm after the cytokine storm: lessons from the TGN1412 trial. J Clin Invest (2008) 1.01
Concise review: the relevance of human stem cell-derived organoid models for epithelial translational medicine. Stem Cells (2013) 0.99
A CD28 superagonistic antibody elicits 2 functionally distinct waves of T cell activation in rats. J Clin Invest (2008) 0.98
CpG and non-CpG oligodeoxynucleotides directly costimulate mouse and human CD4+ T cells through a TLR9- and MyD88-independent mechanism. J Immunol (2011) 0.98
Antibody engineering to develop new antirheumatic therapies. Arthritis Res Ther (2009) 0.97
Severity of the TGN1412 trial disaster cytokine storm correlated with IL-2 release. Br J Clin Pharmacol (2013) 0.96
Comparison of the Superagonist Complex, ALT-803, to IL15 as Cancer Immunotherapeutics in Animal Models. Cancer Immunol Res (2015) 0.96
Pharmacokinetics and toxicology of therapeutic proteins: Advances and challenges. World J Biol Chem (2012) 0.96
After TGN1412: recent developments in cytokine release assays. J Immunotoxicol (2012) 0.92
Screening vaccine formulations for biological activity using fresh human whole blood. Hum Vaccin Immunother (2014) 0.87
Therapeutic down-modulators of staphylococcal superantigen-induced inflammation and toxic shock. Toxins (Basel) (2010) 0.85
Regulating interface science healthcare products: myths and uncertainties. J R Soc Interface (2010) 0.85
Potential role of human-specific genes, human-specific microRNAs and human-specific non-coding regulatory RNAs in the pathogenesis of systemic sclerosis and Sjögren's syndrome. Autoimmun Rev (2013) 0.84
Were monocytes responsible for initiating the cytokine storm in the TGN1412 clinical trial tragedy? Clin Exp Immunol (2010) 0.84
Granzyme B- and Fas ligand-mediated cytotoxic function induced by mitogenic CD28 stimulation of human memory CD4+ T cells. J Leukoc Biol (2012) 0.84
Selective expansion of memory CD4(+) T cells by mitogenic human CD28 generates inflammatory cytokines and regulatory T cells. Eur J Immunol (2008) 0.82
CD28 family and chronic rejection: "to belatacept...And beyond!". J Transplant (2012) 0.82
Preclinical screening for acute toxicity of therapeutic monoclonal antibodies in a hu-SCID model. Clin Transl Immunology (2014) 0.81
A pharmacologic perspective on newly emerging T-cell manipulation technologies. Br J Clin Pharmacol (2013) 0.80
Assessing agonistic potential of a candidate therapeutic anti-IL21R antibody. J Transl Med (2010) 0.80
Immunotherapeutic strategies in autoimmune uveitis. Autoimmun Rev (2014) 0.80
Secreted and transmembrane 1A is a novel co-stimulatory ligand. PLoS One (2013) 0.79
Advantages of Papio anubis for preclinical testing of immunotoxicity of candidate therapeutic antagonist antibodies targeting CD28. MAbs (2014) 0.78
Early implementation of QbD in biopharmaceutical development: a practical example. Biomed Res Int (2015) 0.78
The successes and limitations of preclinical studies in predicting the pharmacodynamics and safety of cell-surface-targeted biological agents in patients. Br J Pharmacol (2012) 0.78
Clinical development methodology for infusion-related reactions with monoclonal antibodies. Clin Transl Immunology (2015) 0.78
Applicability of predictive toxicology methods for monoclonal antibody therapeutics: status Quo and scope. Arch Toxicol (2016) 0.78
Approaches to modelling the human immune response in transition of candidates from research to development. J Immunol Res (2014) 0.77
Fully human HER2/cluster of differentiation 3 bispecific antibody triggers potent and specific cytotoxicity of T lymphocytes against breast cancer. Mol Med Rep (2015) 0.77
Adaptive Evolution as a Predictor of Species-Specific Innate Immune Response. Mol Biol Evol (2015) 0.77
Primate models in organ transplantation. Cold Spring Harb Perspect Med (2013) 0.77
Autoimmune response to transthyretin in juvenile idiopathic arthritis. JCI Insight (2016) 0.76
Anti-CD28 Antibody-Initiated Cytokine Storm in Canines. Transplant Direct (2015) 0.76
CD28 ligation increases macrophage suppression of T-cell proliferation. Cell Mol Immunol (2012) 0.76
TGN1412 Induces Lymphopenia and Human Cytokine Release in a Humanized Mouse Model. PLoS One (2016) 0.76
Delivering safer immunotherapies for cancer. Adv Drug Deliv Rev (2017) 0.76
Failure to upregulate cell surface PD-1 is associated with dysregulated stimulation of T cells by TGN1412-like CD28 superagonist. MAbs (2014) 0.75
Immunotoxicity assessment of rice-derived recombinant human serum albumin using human peripheral blood mononuclear cells. PLoS One (2014) 0.75
Biology-inspired microphysiological system approaches to solve the prediction dilemma of substance testing. ALTEX (2016) 0.75
Unraveling the Effect of Immunogenicity on the PK/PD, Efficacy, and Safety of Therapeutic Proteins. J Immunol Res (2016) 0.75
Development of an in vitro potency assay for anti-anthrax lethal toxin neutralizing antibodies. Toxins (Basel) (2012) 0.75
Novel CD28 antagonist mPEG PV1-Fab' mitigates experimental autoimmune uveitis by suppressing CD4+ T lymphocyte activation and IFN-γ production. PLoS One (2017) 0.75
Safety Profile of Amnion-Derived Cellular Cytokine Solution (ACCS) Following Topical Skin Application in Patients Receiving Breast Radiotherapy. Eplasty (2015) 0.75
Cytokine release assays for the prediction of therapeutic mAb safety in first-in man trials--Whole blood cytokine release assays are poorly predictive for TGN1412 cytokine storm. J Immunol Methods (2015) 0.75
Human tissue in the evaluation of safety and efficacy of new medicines: a viable alternative to animal models? ISRN Pharm (2011) 0.75
Spinal glia and proinflammatory cytokines mediate mirror-image neuropathic pain in rats. J Neurosci (2003) 2.87
Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer. J Natl Cancer Inst (2004) 2.41
Biosimilars: what clinicians should know. Blood (2012) 2.28
Biological activity of interleukins-28 and -29: comparison with type I interferons. Cytokine (2005) 2.27
Infusion of pharmaceutical-grade natural human C-reactive protein is not proinflammatory in healthy adult human volunteers. Circ Res (2013) 2.26
Hypernociceptive role of cytokines and chemokines: targets for analgesic drug development? Pharmacol Ther (2006) 2.13
Proinflammatory cytokines oppose opioid-induced acute and chronic analgesia. Brain Behav Immun (2008) 1.92
The primacy of public health considerations in defining poor quality medicines. PLoS Med (2011) 1.91
Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo. Nat Biotechnol (2009) 1.90
Chemokine/chemokine receptor nomenclature. J Interferon Cytokine Res (2002) 1.86
Initial and maintenance naltrexone treatment for alcohol dependence using primary care vs specialty care: a nested sequence of 3 randomized trials. Arch Intern Med (2003) 1.74
Biosimilars-why terminology matters. Nat Biotechnol (2011) 1.73
Crucial role of neutrophils in the development of mechanical inflammatory hypernociception. J Leukoc Biol (2008) 1.64
Cardiopulmonary resuscitation feedback improves the quality of chest compression provided by hospital health care professionals. Am J Emerg Med (2010) 1.58
Biomarkers of vitamin B-12 status in NHANES: a roundtable summary. Am J Clin Nutr (2011) 1.43
Biomarkers of folate status in NHANES: a roundtable summary. Am J Clin Nutr (2011) 1.43
Rat brain vascular distribution of interleukin-1 type-1 receptor immunoreactivity: relationship to patterns of inducible cyclooxygenase expression by peripheral inflammatory stimuli. J Comp Neurol (2004) 1.41
Access to the guide to professional conduct. Vet Rec (2002) 1.39
The viral mimic, polyinosinic:polycytidylic acid, induces fever in rats via an interleukin-1-dependent mechanism. Am J Physiol Regul Integr Comp Physiol (2004) 1.38
In support of the European Union biosimilar framework. Nat Biotechnol (2012) 1.33
Antinociceptive effects of interleukin-4, -10, and -13 on the writhing response in mice and zymosan-induced knee joint incapacitation in rats. J Pharmacol Exp Ther (2003) 1.30
Recollection and familiarity in dense hippocampal amnesia: a case study. Neuropsychologia (2005) 1.23
Circulating interleukin-6 induces fever through a STAT3-linked activation of COX-2 in the brain. Am J Physiol Regul Integr Comp Physiol (2006) 1.20
Tumour necrosis factor-alpha, interleukin-1beta and interleukin-8 induce persistent mechanical nociceptor hypersensitivity. Pain (2002) 1.15
Safety of biologics, lessons learnt from TGN1412. Curr Opin Biotechnol (2009) 1.12
Pure red cell aplasia induced by erythropoiesis-stimulating agents. Clin J Am Soc Nephrol (2008) 1.11
Peri-sciatic proinflammatory cytokines, reactive oxygen species, and complement induce mirror-image neuropathic pain in rats. Pain (2004) 1.11
Antihyperalgesic effect of pentoxifylline on experimental inflammatory pain. Br J Pharmacol (2004) 1.09
Interleukin-6 in combination with its soluble IL-6 receptor sensitises rat skin nociceptors to heat, in vivo. Pain (2002) 1.08
How predictive are in vitro assays for cytokine release syndrome in vivo? A comparison of methods reveals worrying differences in sensitivity and frequency of response. Cytokine (2013) 1.08
Cytokine-induced neutrophil chemoattractant 1 (CINC-1) mediates the sympathetic component of inflammatory mechanical hypersensitivitiy in rats. Eur Cytokine Netw (2003) 1.07
Interleukin-6 and leptin mediate lipopolysaccharide-induced fever and sickness behavior. Physiol Behav (2006) 1.07
CD8+ lymphocytes do not mediate protection against acute superinfection 20 days after vaccination with a live attenuated simian immunodeficiency virus. J Virol (2005) 1.05
Cytokine gene expression in a murine wound healing model. Cytokine (2005) 1.04
Preparation and characterization of new WHO reference reagents for human chorionic gonadotropin and metabolites. Clin Chem (2003) 1.03
Interleukin-6 mediates low-threshold mechanical allodynia induced by intrathecal HIV-1 envelope glycoprotein gp120. Brain Behav Immun (2007) 1.02
Antigen-induced inflammatory mechanical hypernociception in mice is mediated by IL-18. Brain Behav Immun (2006) 1.02
Naltrexone alone and with sertraline for the treatment of alcohol dependence in Alaska natives and non-natives residing in rural settings: a randomized controlled trial. Alcohol Clin Exp Res (2008) 1.01
Enduring reversal of neuropathic pain by a single intrathecal injection of adenosine 2A receptor agonists: a novel therapy for neuropathic pain. J Neurosci (2009) 1.01
Genetic modifiers of abnormal organelle biogenesis in a Drosophila model of BLOC-1 deficiency. Hum Mol Genet (2009) 1.00
International validation of novel pyrogen tests based on human monocytoid cells. J Immunol Methods (2005) 0.99
IL-1-driven endogenous IL-10 production protects against the systemic and local acute inflammatory response following intestinal reperfusion injury. J Immunol (2003) 0.97
Role of cytokines in mediating mechanical hypernociception in a model of delayed-type hypersensitivity in mice. Eur J Pain (2008) 0.97
Severity of the TGN1412 trial disaster cytokine storm correlated with IL-2 release. Br J Clin Pharmacol (2013) 0.96
Lifestyle and self-care advice within traditional acupuncture consultations: a qualitative observational study nested in a co-operative inquiry. J Altern Complement Med (2011) 0.96
Measuring blood pressure in children. BMJ (2008) 0.96
Consistent manufacturing and quality control of a highly complex recombinant polyclonal antibody product for human therapeutic use. Biotechnol Bioeng (2011) 0.96
Improved in vitro methods to predict the in vivo toxicity in man of therapeutic monoclonal antibodies including TGN1412. J Immunol Methods (2009) 0.95
Interleukin (IL)-6 and IL-1 beta act synergistically within the brain to induce sickness behavior and fever in rats. Brain Behav Immun (2008) 0.95
Nociceptive effect of subcutaneously injected interleukin-12 is mediated by endothelin (ET) acting on ETB receptors in rats. J Pharmacol Exp Ther (2005) 0.95
Utilization of imaging in pregnant patients: 10-year review of 5270 examinations in 3285 patients--1997-2006. Radiology (2009) 0.94
Circulating leptin mediates lipopolysaccharide-induced anorexia and fever in rats. J Physiol (2004) 0.94
TNF-alpha and IL-1beta mediate inflammatory hypernociception in mice triggered by B1 but not B2 kinin receptor. Eur J Pharmacol (2007) 0.93
Continuous delivery of human type I interferons (alpha/beta) has significant activity against acute myeloid leukemia cells in vitro and in a xenograft model. Blood (2006) 0.92
Attenuated fever in rats during late pregnancy is linked to suppressed interleukin-6 production after localized inflammation with turpentine. J Physiol (2007) 0.92
Differences in the relative involvement of peripherally released interleukin (IL)-6, brain IL-1β and prostanoids in mediating lipopolysaccharide-induced fever and sickness behavior. Psychoneuroendocrinology (2010) 0.91
Developments in clinical cell therapy. Cytotherapy (2010) 0.91
Comparative cell signalling activity of ultrapure recombinant chaperonin 60 proteins from prokaryotes and eukaryotes. Immunology (2005) 0.91
Differential regulation of type I and type II interleukin-1 receptors in focal brain inflammation. Eur J Neurosci (2005) 0.90
The critical role of leukotriene B4 in antigen-induced mechanical hyperalgesia in immunised rats. Br J Pharmacol (2003) 0.90
Attitudes toward obsessive-compulsive disorders--an experimental investigation. Soc Psychiatry Psychiatr Epidemiol (2003) 0.89
Release of plasmid DNA-encoding IL-10 from PLGA microparticles facilitates long-term reversal of neuropathic pain following a single intrathecal administration. Pharm Res (2010) 0.89
Pre- and post-natal stress in context: effects on the stress physiology in a precocial bird. J Exp Biol (2012) 0.89
In vitro cytokine release assays for predicting cytokine release syndrome: the current state-of-the-science. Report of a European Medicines Agency Workshop. Cytokine (2010) 0.89
Selective contribution of interleukin-6 and leptin to brain inflammatory signals induced by systemic LPS injection in mice. J Comp Neurol (2008) 0.89
Dual effect of central injection of recombinant rat interleukin-4 on lipopolysaccharide-induced sickness behavior in rats. Neuropsychopharmacology (2002) 0.88
Effect of a BLT receptor antagonist in a model of severe ischemia and reperfusion injury in the rat. Eur J Pharmacol (2002) 0.88
Selective cleavage of human IgG by the matrix metalloproteinases, matrilysin and stromelysin. Immunol Lett (2002) 0.87
Using a medical simulation center as an electronic health record usability laboratory. J Am Med Inform Assoc (2013) 0.87
European perspective on biosimilars. Bioanalysis (2013) 0.87
An assessment of biological potency and molecular characteristics of different innovator and noninnovator interferon-beta products. J Interferon Cytokine Res (2010) 0.86
Calcifying fibrous tumour: an unusual omental lesion. Pediatr Radiol (2008) 0.86